Multiple sclerosis market to be worth $32.9bn in 2028

07:49 EST 11 Dec 2019 | Pharmafile

The multiple sclerosis (MS) market is expected to see a growth in sales, and increase from $19.8 billion in 2018 to $32.9 billion in 2028.

This is due to the launch of 11 new pipeline agents, providing more options and stimulating further competition.

This is according to GlobalData’s latest report: Multiple Sclerosis – Global Drug Forecast and Market Analysis to 2028. It also details how a further 14 late-stage drug products will launch in the seven major markets during, or shortly after, the forecast.

read more

Original Article: Multiple sclerosis market to be worth $32.9bn in 2028


More From BioPortfolio on "Multiple sclerosis market to be worth $32.9bn in 2028"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...